Clindamycin
| Evidence Level: L5 | Predicted Indications: 6 |
Table of Contents
- Clindamycin
- Pharmacist Assessment Report
- Clindamycin: lincosamide antibiotic (bacterial protein synthesis inhibitor) → punctate epithelial keratoconjunctivitis
- One-Sentence Summary
- Quick Overview
- Why is This Prediction Reasonable?
- Clinical Trial Evidence
- Literature Evidence
- Canada Market Information
- Safety Considerations
- Conclusion and Next Steps
- Disclaimer
Clindamycin: lincosamide antibiotic (bacterial protein synthesis inhibitor) → punctate epithelial keratoconjunctivitis
One-Sentence Summary
Clindamycin is a lincosamide antibiotic that blocks bacterial protein synthesis. The TxGNN model predicts it may be useful for punctate epithelial keratoconjunctivitis, with a score of 0.9997. However, no clinical trials and no publications were found for this prediction, so it rests on the model output alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | punctate epithelial keratoconjunctivitis |
| TxGNN Prediction Score | 0.9997 |
| Evidence Level | L5 |
| Canada Market Status | Marketed (marketed DINs on record: at least 18; cancelled: 2) |
| Number of DINs | at least 20 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Clindamycin binds the 50S ribosomal subunit of bacteria and stops protein synthesis. It is active mainly against gram-positive organisms and anaerobes. Detailed mechanism data were not available in the data compiled for this report, so this description reflects the general known class action.
The link to punctate epithelial keratoconjunctivitis is weak. This condition is often viral or non-infectious (for example adenoviral, toxic, or dry-eye related), and an antibacterial has no clear role in these forms. A rationale exists only if a bacterial component is present, such as staphylococcal blepharokeratoconjunctivitis. The prediction is therefore a computational signal, not a mechanism-based expectation. Topical ocular clindamycin is also not an established formulation.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Canada Market Information
No indication text, dosage form or manufacturer is recorded for these licences. Examples of listed products:
| DIN | Product Name |
|---|---|
| 02408511 | CLINDAMYCIN IV INFUSION |
| 02400529 | CLINDAMYCIN |
| 02230535 | CLINDAMYCIN INJECTION USP |
| 02266938 | TARO-CLINDAMYCIN |
| 00260436 | DALACIN C PHOSPHATE |
Safety Considerations
- Drug Interactions: The interaction screen returned 100 entries. Moderate-level ones include balsalazide, clarithromycin, picosulfuric acid, attapulgite and kaolin. Many other entries, such as vancomycin, amoxicillin, doxycycline, metformin, morphine and omeprazole, have an unknown severity level.
Please refer to the package insert for warnings and contraindications, as label-based data were not available.
Conclusion and Next Steps
Decision: Hold
Rationale: The score is very high (0.9997), but there are no trials or publications on this disease, so the evidence level is L5. The plausible mechanism is limited to secondary bacterial infection, and no ocular formulation is established.
To proceed, the following is needed:
- Clinical or preclinical studies of clindamycin in this eye condition, especially with a confirmed bacterial component
- Evidence on a suitable ocular formulation and route
- Package insert warnings and contraindications from Health Canada
- Detailed mechanism of action data
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.